Identification of a novel TNRC18-RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML-RARA.
Chromosomes, Human, Pair 15
/ genetics
Chromosomes, Human, Pair 17
/ genetics
Gene Expression Regulation, Leukemic
Humans
In Situ Hybridization, Fluorescence
Intracellular Signaling Peptides and Proteins
/ genetics
Leukemia, Promyelocytic, Acute
/ genetics
Male
Middle Aged
Oncogene Proteins, Fusion
/ genetics
Retinoic Acid Receptor alpha
/ genetics
Translocation, Genetic
PML-RARA
RARA
TNRC18
acute promyelocytic leukemia
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
22
10
2020
revised:
12
12
2020
accepted:
20
12
2020
pubmed:
12
1
2021
medline:
23
3
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Acute promyelocytic leukemia (APL) is a unique disease entity in acute myeloid leukemia, characterized by PML-RARA fusion gene, which is generated by chromosomal translocation t(15;17)(q24;q21). We identified TNRC18-RARA as novel RARA fusion in resembling APL. Our study highlights the importance of combining multiple molecular techniques to characterize and optimally manage APL lacking classic t(15;17)(q24;q12)/PML-RARA fusion.
Substances chimiques
Intracellular Signaling Peptides and Proteins
0
Oncogene Proteins, Fusion
0
RARA protein, human
0
Retinoic Acid Receptor alpha
0
TNRC18 protein, human
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66(4):675-684.
Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295-1305.
Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood. 2003;102(10):3727-3736.
Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocyticleukaemia. Nat Genet. 1997;17(1):109-113.
Redner RL, Chen JD, Rush EA, Li H, Pollock SL. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood. 2000;95(8):2683-2690.
Kusakabe M, Suzukawa K, Nanmoku T, et al. Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding. Eur J Haematol. 2008;80(5):444-447.
Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008;93(9):1414-1416.
Catalano A, Dawson MA, Somana K, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2007;110(12):4073-4076.
Ichikawa S, Ichikawa S, Ishikawa I, Takahashi T, Fujiwara T, Harigae H. Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene. Cancer Genet. 2015;208(4):162-163.
Won D, Shin SY, Park CJ, et al. OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia. Blood. 2013;121(8):1432-1435.
Chen Y, Li S, Zhou C, et al. TBLR1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood. 2014;124(6):936-945.
Osumi T, Tsujimoto S, Tamura M, et al. Recurrent RARB translocations in acute promyelocytic leukemia lacking RARA translocation. Cancer Res. 2018;78(16):4452-4458.
Li J, Zhong HY, Zhang Y, et al. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocyticleukaemia with clinical resistance to retinoic acid. Br J Haematol. 2015;168(6):904-908.
Jovanovic JV, Chillón MC, Vincent-Fabert C, et al. The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia. Leukemia. 2017;31(3):747-751.
Cheng CK, Wang AZ, Wong THY, et al. FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia. Blood. 2017;129(19):2705-2709.
Yao L, Wen L, Wang N, et al. Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA. Blood. 2018;131(8):935-939.
Chong ML, Cheng H, Xu P, et al. TFG-RARA: a novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid. Leuk Res. 2018;74:51-54.
Licht JD. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell. 2006;9(2):73-74.
Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93(10):3167-3215.